Treatment
recombinant humanized anti-CD25 monoclonal antibody clinical trials
We’re tracking 4 recruiting studies that include recombinant humanized anti-CD25 monoclonal antibody, each written for real people, not researchers, below.
Recruiting studies
- NCT06657391RecruitingPhase 2
Study of a new drug to prevent graft-versus-host disease in thalassemia patients
This trial tests a drug called an anti-CD25 antibody to see if it can prevent graft-versus-host disease (a condition where donor cells attack the body) in people with transfusion-dependent thalassemia who are getting a stem cell transplant from a partially matched or unrelated donor.
Maoming, GuangdongAges 3–20 - NCT07029958RecruitingPhase 4
Transplant protocol for EBV-related T/NK lymphoproliferative disease
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
BeijingAges birth–18 years - NCT06880419RecruitingPhase 2
Anti-CD25 antibody to prevent graft-versus-host disease in high-risk adults
This trial tests whether an antibody called anti-CD25 can help prevent a serious side effect (graft-versus-host disease) in adults getting a stem cell transplant for blood disorders. It is for people considered high-risk based on a special scoring model.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT04871607RecruitingPhase 2
Yttrium antibody plus chemotherapy for hard-to-treat Hodgkin lymphoma
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
Duarte, CaliforniaAges 18 years+
What recombinant humanized anti-CD25 monoclonal antibody is being studied for
Conditions with recruiting recombinant humanized anti-CD25 monoclonal antibody studies.
Common questions
- Are there clinical trials studying recombinant humanized anti-CD25 monoclonal antibody?
- Yes. Clin2 currently lists 4 recruiting studies that include recombinant humanized anti-CD25 monoclonal antibody, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a recombinant humanized anti-CD25 monoclonal antibody trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is recombinant humanized anti-CD25 monoclonal antibody an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether recombinant humanized anti-CD25 monoclonal antibody or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.